

Date and Time: *Thursday 12th September 2013, 10:00-16:00*

Minutes: [Final](#)

Guideline Development Group Meeting 9 Lipid Modification (update)

Place: *National Clinical Guideline Centre, Boardroom
180 Great Portland Street, London W1W 5QZ*

Present:

Anthony Wierzbicki (Chair)	(Present for notes 1 – 6)
Lindsay Banks (Pharmacist)	(Present for notes 1 – 6)
Liz Clark (Patient/carer member)	(Present for notes 1 – 6)
Martin Duerden (General practitioner)	(Present for notes 1 – 6)
Eleanor Grey (Patient/carer member)	(Present for notes 1 – 6)
Michael Khan (Diabetologist)	(Present for notes 1 – 6)
Emma McGowan (Nurse)	(Present for notes 1 – 6)
Dermot Neely (Chemical pathologist and lipidologist)	(Present for notes 1 – 6)
Nadeem Qureshi (General practitioner)	(Present for notes 1 – 6)
Alan Rees (Metabolic/general medicine/elderly care physician)	(Present for notes 1 – 6)
David Wheeler (Co-opted member)	(Present for notes 1 – 6)
Angela Cooper (Senior research fellow)	(Present for notes 1 – 3)
Martin Harker (Health economist)	(Present for notes 1 – 6)
Norma O’Flynn (Clinical director)	(Present for notes 1 – 6)
Silvia Rabar (Senior project manager and research fellow)	(Present for notes 1 – 6)
David Wonderling (Head of health economics)	(Present for notes 1 – 6)

In attendance:

NICE Staff:		
Caroline Keir	(Guideline commissioning manager, NICE)	(Present for notes 1 – 6)

Observers:

--	--	--

Notes

1. The Chair welcomed the group to the ninth meeting of this GDG. Apologies were received from Alan Rees, Rajai Ahmad, and Lina Gulhane and. The Chair asked all GDG members to declare any relevant conflicts of interest. The following interests were declared
 - 1.1. David Wheeler
Personal pecuniary interest:
Consultancy fees: Amgen, Baxter.
Honoraria: Astellas, Baxter, MSD, Viforpharma, Amgen, Otsuka, Fresenius and Shire.
Non-personal pecuniary interest:
Research grants: Genzyme and Abbott.
3. An update was then given to the GDG on progress since the last meeting.
4. The Chair introduced Silvia Rabar, senior project manager and research fellow at NCGC, who gave presentation on the clinical and cost effectiveness of statin therapy in people with chronic kidney disease, and on risk assessment tools for predicting the risk of CVD events in adults without established CVD (primary prevention), with chronic kidney disease.
The GDG then discussed the evidence presented in relation to this guideline and drafted recommendations. The Chair thanked Silvia Rabar for her presentation.
5. The Chair introduced Martin Harker, health economist at NCGC, who gave presentation on the proposed health economics model and took questions from the group. The GDG then discussed the strategy for further analysis. The Chair thanked Martin Harker for his presentation.
6. There were no other businesses to discuss. The Chair closed the meeting and thanked everybody for attending.

Date, time and venue of the next meeting

- 12 September 2013, 10:00-16:00, at the National Clinical Guideline Centre, Boardroom, 180 Great Portland Street, London W1W 5QZ